Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 67
Filtrar
1.
Lung Cancer ; 166: 70-75, 2022 04.
Artigo em Inglês | MEDLINE | ID: mdl-35202979

RESUMO

OBJECTIVES: Ground-glass pulmonary opacities (GGOs) are increasingly encountered in routine clinical practice and an accurate differentiation between benign and malignant lesions is crucial. The aim of this study is to evaluate the relationship between radiological features and the actual biological behavior of these nodules. The secondary endpoint is to identify any radiological predictors able to choose the type of surgical resection and the extent of lymphadenectomy. MATERIALS AND METHODS: This single-center retrospective study included all patients, who underwent high resolution computed tomography (HRCT) and surgical resection for GGOs between 2010 and 2020. Histopathological sampling focused on lesion size, histology, growth pattern, amount of lepidic component, percentage of ground-glass (GG), grade of tumor and proliferation index (Ki67). RESULTS: In 56 patients enrolled, 65 lesions (15 pure GG and 50 part-solid) were resected (44 lobectomies, 9 anatomical segmentectomies, 12 wedge resections). A direct significant correlation was found between: the GG at HRCT and the amount of lepidic component (p < 0.0001; R = 0.305), the tumor grading and the lepidic component at HRCT (p = 0.003), the percentage of GG and the expression of Ki67 (p = 0.016), the lepidic percentage and the expression of Ki67 (p = 0.004; R = 0.223). A total of 609 lymph-nodes were removed (stations N1 and N2) and histopathological analysis was negative for nodal involvement in all cases. CONCLUSION: Pure and part-solid GGOs could benefit from less invasive and lung sparing surgery with just nodal sampling. These would reduce surgical complications and guarantee a better quality of life for the patient. The major limitations are the number of patients and the lack of a longer follow-up.


Assuntos
Neoplasias Pulmonares , Humanos , Antígeno Ki-67 , Pulmão/diagnóstico por imagem , Pulmão/patologia , Pulmão/cirurgia , Neoplasias Pulmonares/patologia , Neoplasias Pulmonares/cirurgia , Pneumonectomia/métodos , Qualidade de Vida , Estudos Retrospectivos
3.
Toxicol Appl Pharmacol ; 336: 8-19, 2017 12 01.
Artigo em Inglês | MEDLINE | ID: mdl-28987381

RESUMO

Patients with inflammatory lung diseases are often additionally exposed to polycyclic aromatic hydrocarbons like B[a]P and B[a]P-induced alterations in gene expression in these patients may contribute to the development of lung cancer. Mice were intra-nasally treated with lipopolysaccharide (LPS, 20µg/mouse) to induce pulmonary inflammation and subsequently exposed to B[a]P (0.5mg/mouse) by intratracheal instillation. Gene expression changes were analyzed in mouse lungs by RNA microarrays. Analysis of genes that are known to be involved in the cellular response to B[a]P indicated that LPS significantly inhibited gene expression of various enzymes linked to B[a]P metabolism, which was confirmed by phenotypic analyses of enzyme activity. Ultimately, these changes resulted in higher levels of B[a]P-DNA adducts in the lungs of mice exposed to B[a]P with prior LPS treatment compared to the lungs of mice exposed to B[a]P alone. Using principle component analysis (PCA), we found that of all the genes that were significantly altered in their expression, those that were able to separate the different exposure conditions were predominantly related to immune-response. Moreover, an overall analysis of differentially expressed genes indicated that cell-cell adhesion and cell-cell communication was inhibited in lungs of mice that received both B[a]P and LPS. Our results indicate that pulmonary inflammation increased the genotoxicity of B[a]P via inhibition of both phase I and II metabolism. Therefore, inflammation could be a critical contributor to B[a]P-induced carcinogenesis in humans.


Assuntos
Benzo(a)pireno/toxicidade , Lipopolissacarídeos , Pulmão/efeitos dos fármacos , Pneumonia/genética , Transcriptoma/efeitos dos fármacos , Animais , Benzo(a)pireno/metabolismo , Adutos de DNA/genética , Adutos de DNA/metabolismo , Modelos Animais de Doenças , Perfilação da Expressão Gênica/métodos , Redes Reguladoras de Genes , Mediadores da Inflamação/metabolismo , Pulmão/metabolismo , Masculino , Desintoxicação Metabólica Fase I , Desintoxicação Metabólica Fase II , Camundongos Endogâmicos C57BL , Análise de Sequência com Séries de Oligonucleotídeos , Pneumonia/induzido quimicamente , Pneumonia/metabolismo , Análise de Componente Principal
4.
Handb Exp Pharmacol ; 237: 63-91, 2017.
Artigo em Inglês | MEDLINE | ID: mdl-27844172

RESUMO

Theophylline is an orally acting xanthine that has been used since 1937 for the treatment of respiratory diseases including asthma and chronic obstructive pulmonary disease (COPD). However, in most treatment guidelines, xanthines have now been consigned to third-line therapy because of their narrow therapeutic window and propensity for drug-drug interactions. However, lower than conventional doses of theophylline considered to be bronchodilator are now known to have anti-inflammatory actions of relevance to the treatment of respiratory disease. The molecular mechanism(s) of action of theophylline are not well understood, but several potential targets have been suggested including non-selective inhibition of phosphodiesterases (PDE), inhibition of phosphoinositide 3-kinase, adenosine receptor antagonism and increased activity of certain histone deacetylases. Although theophylline has a narrow therapeutic window, other xanthines are in clinical use that are claimed to have a better tolerability such as doxofylline and bamifylline. Nonetheless, xanthines still play an important role in the treatment of asthma and COPD as they can show clinical benefit in patients who are refractory to glucocorticosteroid therapy, and withdrawal of xanthines from patients causes worsening of disease, even in patients taking concomitant glucocorticosteroids.More recently the orally active selective PDE4 inhibitor, roflumilast, has been introduced into clinical practice for the treatment of severe COPD on top of gold standard treatment. This drug has been shown to improve lung function in patients with severe COPD and to reduce exacerbations, but is dose limited by a range side effect, particularly gastrointestinal side effects.


Assuntos
Asma/tratamento farmacológico , Inibidores de Fosfodiesterase/uso terapêutico , Doença Pulmonar Obstrutiva Crônica/tratamento farmacológico , Xantinas/uso terapêutico , Animais , Contraindicações , Humanos , Inibidores da Fosfodiesterase 4/uso terapêutico , Inibidores de Fosfoinositídeo-3 Quinase , Teofilina/farmacologia , Teofilina/uso terapêutico , Xantinas/administração & dosagem , Xantinas/efeitos adversos
5.
Pathologica ; 108(1): 38-41, 2016 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-28195247

RESUMO

Pulmonary congenital abnormalities are rare disorders including congenital pulmonary airway malformations (CPAM) and pulmonary sequestration (PS). CPAM is a lesion characterized by the presence of anomalous bronchiolar or acinar structures, variable in size, either cystic or not cystic. PS is generally defined as nonfunctioning lung tissue that is not in normal continuity with the tracheobronchial tree and that derives its blood supply from systemic vessels. We describe a case of a baby girl with a very rare association between CPAM type 2 and intralobar pulmonary sequestration (IPS) focusing on the cystic lesions typical of CPAM and on the lymphatic and blood vessels. The cells lining the cysts often were positive for D2-40 (oncofetal protein M2A). Lymphatic endothelial cells, positive for D2-40, were widely present in the lung parenchyma and dilated lymphatic vessels were present also in the inter-alveolar septa. Moreover, we discuss the pathogenesis of CPAM and its classification criteria.


Assuntos
Sequestro Broncopulmonar/patologia , Malformação Adenomatoide Cística Congênita do Pulmão/patologia , Anticorpos Monoclonais Murinos , Antígenos de Neoplasias/análise , Sequestro Broncopulmonar/cirurgia , Malformação Adenomatoide Cística Congênita do Pulmão/cirurgia , Feminino , Humanos , Imuno-Histoquímica , Recém-Nascido , Pneumonectomia
6.
Arch Toxicol ; 90(9): 2261-2273, 2016 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-26438400

RESUMO

Neutrophils infiltrate tissues during inflammation, and when activated, they release ß-glucuronidase. Since inflammation is associated with carcinogenesis, we investigated how extracellular ß-glucuronidase changed the in vitro cellular response to the chemical carcinogen benzo(a)pyrene (B[a]P). For this we exposed human liver (HepG2) and lung (A549) cells to B[a]P in the presence or absence of ß-glucuronidase. ß-Glucuronidase reduced B[a]P-induced expression of CYP1A1 and CYP1B1 at 6 h after exposure, which did not depend on ß-glucuronidase activity, because the inhibitor D-saccharic acid 1,4-lactone monohydrate did not antagonize the effect of ß-glucuronidase. On the other hand, the inhibitory effect of ß-glucuronidase on CYP expression was dependent on signalling via the insulin-like growth factor receptor (IGF2R, a known receptor for ß-glucuronidase), because co-incubation with the IGF2R inhibitor mannose-6-phosphate completely abolished the effect of ß-glucuronidase. Extracellular ß-glucuronidase also reduced the formation of several B[a]P metabolites and B[a]P-DNA adducts. Interestingly, at 24 h of exposure, ß-glucuronidase significantly enhanced CYP expression, probably because ß-glucuronidase de-glucuronidated B[a]P metabolites, which continued to trigger the aryl hydrocarbon receptor (Ah receptor) and induced expression of CYP1A1 (in both cell lines) and CYP1B1 (in A549 only). Consequently, significantly higher concentrations of B[a]P metabolites and DNA adducts were found in ß-glucuronidase-treated cells at 24 h. DNA adduct levels peaked at 48 h in cells that were exposed to B[a]P and treated with ß-glucuronidase. Overall, these data show that ß-glucuronidase alters the cellular response to B[a]P and ultimately enhances B[a]P-induced DNA adduct levels.


Assuntos
Benzo(a)pireno/toxicidade , Carcinógenos/toxicidade , Glucuronidase/farmacologia , Hepatócitos/efeitos dos fármacos , Pulmão/efeitos dos fármacos , Pneumonia/enzimologia , Animais , Fatores de Transcrição Hélice-Alça-Hélice Básicos/agonistas , Fatores de Transcrição Hélice-Alça-Hélice Básicos/metabolismo , Benzo(a)pireno/metabolismo , Biotransformação , Carcinógenos/metabolismo , Citocromo P-450 CYP1A1/genética , Citocromo P-450 CYP1A1/metabolismo , Citocromo P-450 CYP1B1/genética , Citocromo P-450 CYP1B1/metabolismo , Adutos de DNA/metabolismo , Modelos Animais de Doenças , Células Hep G2 , Hepatócitos/enzimologia , Hepatócitos/patologia , Humanos , Lipopolissacarídeos , Pulmão/enzimologia , Pulmão/patologia , Pneumonia/induzido quimicamente , Pneumonia/genética , Pneumonia/patologia , Receptor IGF Tipo 2/agonistas , Receptor IGF Tipo 2/metabolismo , Receptores de Hidrocarboneto Arílico/agonistas , Receptores de Hidrocarboneto Arílico/metabolismo , Transdução de Sinais/efeitos dos fármacos , Fatores de Tempo
7.
J Control Release ; 210: 1-9, 2015 Jul 28.
Artigo em Inglês | MEDLINE | ID: mdl-25980621

RESUMO

The development of clinically acceptable albumin-based nanoparticle formulations for use in pulmonary drug delivery has been hindered by concerns about the toxicity of nanomaterials in the lungs combined with a lack of information on albumin nanoparticle clearance kinetics and biodistribution. In this study, the in vivo biocompatibility of albumin nanoparticles was investigated following a single administration of 2, 20, and 390µg/mouse, showing no inflammatory response (TNF-α and IL-6, cellular infiltration and protein concentration) compared to vehicle controls at the two lower doses, but elevated mononucleocytes and a mild inflammatory effect at the highest dose tested. The biodistribution and clearance of (111)In labelled albumin solution and nanoparticles over 48h following a single pulmonary administration to mice was investigated by single photon emission computed tomography and X-ray computed tomography imaging and terminal biodistribution studies. (111)In labelled albumin nanoparticles were cleared more slowly from the mouse lung than (111)In albumin solution (64.1±8.5% vs 40.6±3.3% at t=48h, respectively), with significantly higher (P<0.001) levels of albumin nanoparticle-associated radioactivity located within the lung tissue (23.3±4.7%) compared to the lung fluid (16.1±4.4%). Low amounts of (111)In activity were detected in the liver, kidneys, and intestine at time points >24h indicating that small amounts of activity were cleared from the lungs both by translocation across the lung mucosal barrier, as well as mucociliary clearance. This study provides important information on the fate of albumin vehicles in the lungs, which may be used to direct future formulation design of inhaled nanomedicines.


Assuntos
Sistemas de Liberação de Medicamentos , Nanopartículas , Soroalbumina Bovina/farmacocinética , Administração por Inalação , Animais , Líquido da Lavagem Broncoalveolar/citologia , Contagem de Células , Interleucina-6/metabolismo , Mucosa Intestinal/metabolismo , Rim/metabolismo , Fígado/embriologia , Pulmão/metabolismo , Masculino , Camundongos Endogâmicos BALB C , Nanopartículas/administração & dosagem , Óxido Nítrico/metabolismo , Soroalbumina Bovina/administração & dosagem , Soroalbumina Bovina/farmacologia , Distribuição Tecidual , Fator de Necrose Tumoral alfa/metabolismo
8.
Scott Med J ; 59(1): 22-9, 2014 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-24463694

RESUMO

BACKGROUND AND AIMS: Although the management of thymomas has been extensively evaluated, the value of prognostic factors in the outcome of these patients remains unclear. METHODS AND RESULTS: The medical records of all patients who underwent resection of thymoma between January 1985 and September 2010 at a single thoracic unit were reviewed. Patients were followed up with reference to disease recurrence and development of additional malignancies (AM). Total thymectomy was performed in all 68 cases. Mean follow-up time was four years. Mean survival was 63.9 months. Mean disease-free interval was 13 months. Factors affecting prognosis were Masaoka staging and WHO histological sub-type. Patients with thymomas had a higher risk of developing AM when compared with a control population of individuals with other tumours (p = 0.0002). Among thymomas, the cortical subtype was associated with a higher risk of AM (p = 0.047) and mortality (p = 0.001). CONCLUSIONS: This data confirms that Masaoka staging and WHO histologic sub-type are the most important prognostic factors in patients with thymoma. Moreover, thymomas predominantly arising from the thymic cortex are associated with a higher risk of developing other malignancies and with poorer survival. The cortical origin of thymoma could therefore be considered as a significant prognostic factor.


Assuntos
Segunda Neoplasia Primária/epidemiologia , Timoma/cirurgia , Neoplasias do Timo/cirurgia , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Terapia Combinada , Progressão da Doença , Feminino , Seguimentos , Humanos , Masculino , Pessoa de Meia-Idade , Recidiva Local de Neoplasia , Estadiamento de Neoplasias , Prognóstico , Estudos Retrospectivos , Análise de Sobrevida , Timectomia , Timoma/mortalidade , Timoma/terapia , Neoplasias do Timo/mortalidade , Neoplasias do Timo/terapia
9.
J Clin Microbiol ; 50(5): 1742-4, 2012 May.
Artigo em Inglês | MEDLINE | ID: mdl-22403425

RESUMO

We assessed a new screening method, based on δ-hemolysin production in the presence of 6 mg/liter vancomycin, to distinguish heteroresistant vancomycin-intermediate Staphylococcus aureus (hVISA) and vancomycin-intermediate S. aureus (VISA) from vancomycin-susceptible S. aureus (VSSA). On 37 clinical methicillin-resistant S. aureus (MRSA) isolates, hVISA and VISA displayed no δ-hemolysis whereas VSSA displayed strong δ-hemolysis, showing 91.6% sensitivity. These data, supported by real-time reverse transcription PCR (real-time RT-PCR) highlighting an hld downregulation, i.e., VSSA>hVISA>VISA, define this new assay as a valid screening method.


Assuntos
Proteínas de Bactérias/metabolismo , Técnicas Bacteriológicas/métodos , Meios de Cultura/química , Proteínas Hemolisinas/metabolismo , Hemólise , Staphylococcus aureus Resistente à Meticilina/efeitos dos fármacos , Staphylococcus aureus Resistente à Meticilina/isolamento & purificação , Resistência a Vancomicina , Antibacterianos/farmacologia , Proteínas de Bactérias/genética , Proteínas Hemolisinas/genética , Humanos , Programas de Rastreamento/métodos , Staphylococcus aureus Resistente à Meticilina/genética , Reação em Cadeia da Polimerase em Tempo Real , Reação em Cadeia da Polimerase Via Transcriptase Reversa , Infecções Estafilocócicas/microbiologia , Vancomicina/farmacologia
10.
Br J Pharmacol ; 165(6): 1978-1991, 2012 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-21951209

RESUMO

BACKGROUND AND PURPOSE: TNF-α is an inflammatory cytokine implicated in the pathogenesis of asthma and it causes airway inflammation, bronchoconstriction and airway hyperresponsiveness to a number of spasmogens following inhalation. EXPERIMENTAL APPROACH: We compared contractions of guinea pig isolated trachea incubated with saline or TNF-α for 1, 2 or 4 days to electrical field stimulation (EFS), 5-HT or methacholine. In addition, we compared bronchoconstriction in anaesthetized guinea pigs 6 h after intratracheal instillation of saline or TNF-α to vagal nerve stimulation, i.v. 5-HT or methacholine. Differential counts were performed on the bronchoalvelolar lavage fluid (BALF). KEY RESULTS: Maximum contractions to methacholine, 5-HT and EFS were not different between freshly prepared and saline-incubated tissues. Exposure to TNF-α concentration-dependently potentiated contractions to 5-HT and EFS, but not methacholine. All contractions were atropine-sensitive, but not hexamethonium-sensitive. 5-HT-evoked contractions were inhibited by ketanserin or epithelial denudation. Only EFS-evoked contractions were tetrodotoxin-sensitive. Vagal stimulation, i.v. 5-HT or MCh caused a significant atropine-sensitive, frequency- and dose-dependent bronchoconstriction and decreased blood pressure similarly in both saline and TNF-α pre-treated animals. TNF-α potentiated the bronchoconstriction to vagal stimulation and 5-HT, but not MCh. The BALF from saline-treated animals contained predominantly macrophages, whereas that from TNF-α-treated animals contained neutrophils. CONCLUSIONS AND IMPLICATIONS: TNF-α caused airway hyperresponsiveness to nerve stimulation in vivo and increased contractility in vitro. However, responsiveness to MCh was unchanged, suggesting a pre-synaptic action of TNF-α on parasympathetic nerves. TNF-α-induced airway hyperresponsiveness to 5-HT suggested an increased 5-HT(2A) receptor-mediated acetylcholine release from epithelial cells.


Assuntos
Hiper-Reatividade Brônquica/fisiopatologia , Contração Muscular/fisiologia , Fator de Necrose Tumoral alfa/fisiologia , Animais , Pressão Sanguínea , Líquido da Lavagem Broncoalveolar/citologia , Contagem de Células , Estimulação Elétrica , Cobaias , Frequência Cardíaca , Técnicas In Vitro , Masculino , Cloreto de Metacolina/farmacologia , Agonistas Muscarínicos/farmacologia , Músculo Liso/fisiologia , Serotonina/farmacologia , Agonistas do Receptor de Serotonina/farmacologia , Traqueia/fisiologia
11.
Handb Exp Pharmacol ; (204): 391-414, 2011.
Artigo em Inglês | MEDLINE | ID: mdl-21695650

RESUMO

Phosphodiesterase 4 (PDE4) belongs to a family of enzymes which catalyzes the breakdown of 3, 5'-adenosine cyclic monophosphate (cAMP) and is ubiquitously expressed in inflammatory cells. There is little evidence that inflammatory diseases are caused by increased expression of this isoenzyme, although human inflammatory cell activity can be suppressed by selective PDE4 inhibitors. Consequently, there is intense interest in the development of selective PDE4 inhibitors for the treatment of a range of inflammatory diseases, including asthma, chronic obstructive pulmonary disease (COPD), inflammatory bowel disease, and psoriasis. Recent clinical trials with roflumilast in COPD have confirmed the therapeutic potential of targeting PDE4 and recently roflumilast has been approved for marketing in Europe and the USA, although side effects such as gastrointestinal disturbances, particularly nausea and emesis as well as headache and weight loss, may limit the use of this drug class, at least when administered by the oral route. However, a number of strategies are currently being pursued in attempts to improve clinical efficacy and reduce side effects of PDE4 inhibitors, including delivery via the inhaled route, development of nonemetic PDE4 inhibitors, mixed PDE inhibitors, and/or antisense biologicals targeted toward PDE4.


Assuntos
Inflamação/tratamento farmacológico , Inibidores da Fosfodiesterase 4/uso terapêutico , Animais , Asma/tratamento farmacológico , Asma/etiologia , Nucleotídeo Cíclico Fosfodiesterase do Tipo 4/fisiologia , Humanos , Inibidores da Fosfodiesterase 4/efeitos adversos , Doença Pulmonar Obstrutiva Crônica/tratamento farmacológico , Doença Pulmonar Obstrutiva Crônica/etiologia
12.
Eur J Clin Microbiol Infect Dis ; 29(10): 1277-85, 2010 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-20602245

RESUMO

Methicillin-resistant Staphylococcus aureus (MRSA) infections are increasingly being reported among cystic fibrosis (CF) populations worldwide. In this paper, we sought to examine at the epidemiology, the molecular characterisation and the antibiotic resistance of MRSA isolates in our cohort of CF patients. All MRSA strains were collected prospectively at the University Hospital of Catania, Italy, during a two-year study between mid 2005 to mid 2007 and underwent molecular, pathotype and susceptibility characterisations. Our study demonstrates persisting infections with both hospital-associated (HA-) and community-associated (CA-)MRSA, including Panton-Valentine leukocidin (PVL)-positive strains, in our CF population with an overall prevalence of 7.8%. We demonstrated that, in these patients, persistence was sustained by either identical clones that underwent subtle changes in their toxin content or by different clones over time. The isolation of MRSA in our CF population aged 7-24 years was associated with an increased severity of the disease even if, due to the small sample of patients included and the paucity of data on the clinical outcome, these results cannot be conclusive. Furthermore, three strains were heteroresistant vancomycin-intermediate S. aureus (hVISA), questioning the use of glycopeptides in the treatment of MRSA infections in these patients.


Assuntos
Fibrose Cística/complicações , Resistência a Meticilina , Infecções Estafilocócicas/epidemiologia , Infecções Estafilocócicas/microbiologia , Staphylococcus aureus/efeitos dos fármacos , Resistência a Vancomicina , Adolescente , Toxinas Bacterianas/genética , Técnicas de Tipagem Bacteriana , Criança , Infecções Comunitárias Adquiridas/epidemiologia , Infecções Comunitárias Adquiridas/microbiologia , Infecção Hospitalar/epidemiologia , Infecção Hospitalar/microbiologia , Impressões Digitais de DNA , DNA Bacteriano/genética , Exotoxinas/genética , Genótipo , Humanos , Itália/epidemiologia , Leucocidinas/genética , Testes de Sensibilidade Microbiana , Estudos Prospectivos , Staphylococcus aureus/isolamento & purificação , Fatores de Virulência/genética , Adulto Jovem
13.
J Pharmacol Toxicol Methods ; 61(2): 157-62, 2010.
Artigo em Inglês | MEDLINE | ID: mdl-20193769

RESUMO

INTRODUCTION: Cough is a common medical problem for which there are few effective drug treatments. A limited understanding of the mechanisms of induction and maintenance of cough and a paucity of suitable animal models frustrate drug discovery efforts to find novel anti-tussives. As in humans, guinea-pigs evoke a cough reflex upon exposure to tussive agents such as citric acid and capsaicin; both of which have been widely used to assess novel anti-tussive drugs. However, the potential for using within-group designs in drug development has received little attention and such designs may offer a way of assisting the drug discovery effort in the area of cough as well as other areas. METHODS: Cough can be monitored in conscious guinea-pigs by placing animals in a Perspex chamber, in which air is continually exchanged by use of negative pressure and drug delivery of aerosols to the chamber can be accurately timed. Cough in response to a tussive agent (e.g. 0.2-0.4M citric acid; 10-30 microM capsaicin) is detected by the simultaneous microphonic recording of audible signals characteristic of the cough response as well as by positive pressure changes in the chamber generated by a cough dependent rapid expiration of air from the lungs. Both the sound and pressure signals are recorded using an online analyzer, whilst the number of coughs can be analyzed off-line. The number of coughs over a 15 min period is used to quantitate tussive events. RESULTS: Reproducible cough can be detected in animals using cross-over designs that lend themselves to drug studies. Both the time and concentration dependence of anti-tussive drug action can be evaluated in the same animal. Furthermore, the effect of different anti-tussive drugs can be evaluated thereby reducing between group error and thereby improving the sensitivity of the test. DISCUSSION: Repeated measures design improves the precision with which to evaluate anti-tussive drugs in preclinical models and could be used to make the drug discovery process more efficient.


Assuntos
Antitussígenos/farmacologia , Tosse/tratamento farmacológico , Agonistas Adrenérgicos beta/administração & dosagem , Agonistas Adrenérgicos beta/uso terapêutico , Anestésicos Locais/uso terapêutico , Animais , Capsaicina , Doença Crônica , Ácido Cítrico , Tosse/induzido quimicamente , Tosse/patologia , Estudos Cross-Over , Cobaias , Injeções Intraperitoneais , Lidocaína/uso terapêutico , Masculino , Reprodutibilidade dos Testes , Projetos de Pesquisa , Soluções , Som , Terbutalina/administração & dosagem , Terbutalina/uso terapêutico
14.
Respir Physiol Neurobiol ; 167(3): 261-7, 2009 Jul 31.
Artigo em Inglês | MEDLINE | ID: mdl-19464392

RESUMO

By proteomic approach we previously characterised bronchoalveolar lavage (BAL) protein profiles of patients with idiopathic pulmonary fibrosis (IPF), sarcoidosis and systemic sclerosis. Among differently expressed proteins we identified macrophage migration inhibitory factor (MIF), a multi-function pleiotropic cytokine. This study was performed to validate our findings by a further proteomic approach and ELISA in a larger population of patients and controls. MIF expression in lung tissue was also evaluated by immunohistochemistry. MIF was identified in all 2-DE gels of IPF patients and it was significantly increased compared to controls (p<0.05). This result was confirmed by ELISA: MIF concentrations were significantly higher in IPF patients than controls (p<0.001) and were directly correlated with neutrophil percentages (p=0.0095). Immunohistochemical analysis revealed enhanced expression in bronchiolar epithelium, alveolar epithelium, and fibroblastic foci. In conclusion, MIF is a pleiotropic cytokine that could be involved in the pathogenesis of IPF, being particularly abundant in BAL of these patients and mainly expressed in the areas of active fibrosis.


Assuntos
Fatores Inibidores da Migração de Macrófagos/sangue , Fibrose Pulmonar/sangue , Adulto , Idoso , Gasometria , Líquido da Lavagem Broncoalveolar/citologia , Eletroforese em Gel Bidimensional , Ensaio de Imunoadsorção Enzimática , Feminino , Humanos , Imuno-Histoquímica , Masculino , Pessoa de Meia-Idade , Testes de Função Respiratória , Fumar/efeitos adversos
15.
Minerva Chir ; 64(1): 111-5, 2009 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-19202540

RESUMO

UNLABELLED: Congenital lobar emphysema (CLE) is a rare congenital lung disease consisting in overinflation of a pulmonary lobe. Adult onset of CLE is therefore unusual, often presented with mild symptoms. The authors report a very uncommon case of congenital segmental emphysema diagnosed in a 21-year-old non-smoking man because of recurrent right pneumothorax. Indication to pulmonary resection was established according to functional limitation, radiological findings of right upper lobe segmental emphysema with corresponding bronchial agenesia, scintigraphic result of extremely reduced ventilation and perfusion of lung emphysematous area and recurrency of pneumothorax. The intervention was carried out by 3-portal video-assisted thoracic surgery (VATS) using single-lung ventilation leading to determine precisely how much lung to resect thanks to the obvious and clear-cut distinction between functioning and non functioning parenchyma of the upper lobe. A stapler wedge resection by VATS was thus obtained, that, as far as the author's knowledge, it is the first case of endoscopic parenchymal sparing resection in CLE. Even though congenital lobar emphysema is rare, clinical awareness of this condition is important for early diagnosis and effective surgical treatment that in this case led to favourable RESULTS: The VATS procedure seems to be an advantageous approach.


Assuntos
Enfisema/congênito , Enfisema/cirurgia , Pulmão/patologia , Pneumonectomia/métodos , Cirurgia Torácica Vídeoassistida , Adulto , Diagnóstico Precoce , Enfisema/patologia , Humanos , Masculino , Resultado do Tratamento
16.
Pathologica ; 101(5): 180-2, 2009 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-20218058

RESUMO

Multiple hamartomas of the lung are uncommon. The few cases described to date are multiple parenchymal hamartomas or multiple endobronchial and parenchymal hamartomas. Herein, an original case is described which is characterized by the association between an endobronchial hamartoma and multiple, unusual, bronchial lesions of the peripheral lung.


Assuntos
Broncopatias/patologia , Hamartoma/patologia , Lipomatose/patologia , Broncopatias/cirurgia , Hamartoma/cirurgia , Humanos , Lipomatose/cirurgia , Masculino , Pessoa de Meia-Idade , Pneumonectomia , Fumar
17.
Handb Exp Pharmacol ; (187): 155-86, 2009.
Artigo em Inglês | MEDLINE | ID: mdl-18825340

RESUMO

Cough is an indispensable defensive reflex. Although generally beneficial, it is also a common symptom of diseases such as asthma, chronic obstructive pulmonary disease, upper respiratory tract infections, idiopathic pulmonary fibrosis and lung cancer. Cough remains a major unmet medical need and although the centrally acting opioids have remained the antitussive of choice for decades, they have many unwanted side effects. However, new research into the behaviour of airway sensory nerves has provided greater insight into the mechanisms of cough and new avenues for the discovery of novel non-opioid antitussive drugs. In this review, the pathophysiological mechanisms of cough and the development of novel antitussive drugs are reviewed.


Assuntos
Antitussígenos/farmacologia , Tosse/fisiopatologia , Sistema Nervoso Periférico/efeitos dos fármacos , Sistema Nervoso Periférico/fisiopatologia , Animais , Antitussígenos/uso terapêutico , Tosse/tratamento farmacológico , Humanos , Neurônios Aferentes/efeitos dos fármacos , Neurônios Aferentes/fisiologia , Reflexo/fisiologia
18.
Br J Pharmacol ; 153 Suppl 1: S446-56, 2008 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-18311158

RESUMO

The accumulation of evidence implicating a role for adenosine in the pathogenesis of asthma has led to investigations into all adenosine receptor subtypes as potential therapeutic targets for the treatment of asthma. Selective A(1) receptor antagonists are currently in preclinical development since adenosine has been shown experimentally to mediate various features of asthma through this receptor such as bronchoconstriction, mucus secretion and inflammation. The A(2A) receptor is expressed on most inflammatory cells implicated in asthma, and as A(2A) stimulation activates adenylate cyclase and consequently elevates cAMP, selective A(2A) receptor agonists have now reached clinical development. However, initial reports concerning their efficacy are inconclusive. A(2B) receptor antagonists are also under investigation based on the rationale that inhibiting the effects of adenosine on mast cells would be beneficial, in addition to other reported pro-inflammatory effects mediated by the A(2B) receptor on cells such as airway smooth muscle, epithelial cells and fibroblasts. Whilst the effects in pre-clinical models are promising, their efficacy in the clinical setting has also yet to be reported. Finally, adenosine A(3) receptor stimulation has been demonstrated to mediate inhibitory effects on eosinophils since it also elevates cAMP. However, some experimental reports suggest that A(3) antagonists mediate anti-inflammatory effects, thus the rationale for A(3) receptor ligands as therapeutic agents remains to be determined. In conclusion, establishing the precise role of adenosine in the pathogenesis of asthma and developing appropriate subtype selective agonists/antagonists represents an exciting opportunity for the development of novel therapeutics for the treatment of asthma.


Assuntos
Antiasmáticos/farmacologia , Asma/tratamento farmacológico , Asma/fisiopatologia , Receptores Purinérgicos P1/fisiologia , Adenosina/farmacologia , Adenosina/fisiologia , Animais , Broncoconstrição/efeitos dos fármacos , Humanos , Inflamação/induzido quimicamente , Inflamação/patologia , Receptor A1 de Adenosina/efeitos dos fármacos , Receptor A2A de Adenosina/efeitos dos fármacos , Receptor A3 de Adenosina/efeitos dos fármacos , Receptores Purinérgicos P1/efeitos dos fármacos
19.
J Hematop ; 1(1): 3-10, 2008 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-19669199

RESUMO

Angiogenic switch marks the beginning of tumor's strategy to acquire independent blood supply. In some subtypes of non-Hodgkin's lymphomas, higher local vascular endothelial growth factor (VEGF) expression correlates with increased microvessel density. However, this local VEGF expression is higher only in tumors with elevated expression of the receptors of the growth factor, suggesting an autocrine growth-promoting feedback loop. Several studies have indicated that VEGF receptors are also targeted by Tat protein from the HIV-1-infected cells. Given the similarity of the basic region of Tat to the angiogenic factors (basic fibroblast growth factor, VEGF), Tat mimics these proteins and binds to their receptors. We evaluated the role of HIV-1 Tat in regulating the level of VEGF expression and microvessel density in the AIDS-related diffuse large B-cell (DLBCL) and Burkitt lymphomas (BL). By luciferase assay, we showed that VEGF promoter activity was downregulated in vitro in cells transfected with Tat. Reduced VEGF protein expression in primary HIV-1 positive BL and DLBCL, compared to the negative cases, supported the findings of promoter downregulation from the cell lines. Microvascular density assessed by CD34 expression was, however, higher in HIV-1 positive than in HIV-1 negative tumors. These results suggest that Tat has a wider angiogenic role, besides the regulation of VEGF expression. Thus, targeting Tat protein itself and stabilizing transient silencing of VEGF expression or use of monoclonal antibodies against their receptors in the AIDS-associated tumors will open a window for future explorable pathways in the management of angiogenic phenotypes in the AIDS-associated non-Hodgkin's lymphomas.

20.
Eur Respir J ; 31(2): 311-9, 2008 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-17959644

RESUMO

Asthmatics, unlike healthy subjects, experience bronchoconstriction in response to inhaled adenosine, and extracellular adenosine concentrations are elevated in the bronchoalveolar lavage fluid and exhaled breath condensate of asthmatic subjects. However, little is known about the location and expression of adenosine receptors in asthmatic airways. The aim of the present study was to investigate the distribution of adenosine A(1) receptors in bronchial biopsy specimens from mildly asthmatic steroid-naïve subjects and then compare the degree of expression with that of healthy subjects. Biopsy sections were immunostained using an adenosine A(1) receptor antibody, the selectivity of which was validated in specific experiments. Image analysis was then performed in order to determine differences in immunostaining intensity. Immunostaining of biopsy sections from the asthmatic subjects revealed strong expression of the A(1) receptor, located predominantly in the bronchial epithelium and bronchial smooth muscle. In comparison, very weak immunostaining was observed in biopsy specimens obtained from healthy subjects. Image analysis revealed that the intensity of positive staining of the asthmatic bronchial epithelium and smooth muscle regions was significantly greater than that observed for the healthy epithelium and smooth muscle. In conclusion, the sensitivity of asthmatics to inhaled adenosine coupled with increased adenosine A(1) receptor expression implies that these receptors play a role in the pathophysiology of this disease.


Assuntos
Asma/fisiopatologia , Brônquios/patologia , Hiper-Reatividade Brônquica/diagnóstico , Receptor A1 de Adenosina/metabolismo , Adenosina/administração & dosagem , Administração por Inalação , Asma/patologia , Biomarcadores/análise , Biópsia por Agulha , Testes de Provocação Brônquica , Estudos de Casos e Controles , Feminino , Volume Expiratório Forçado , Humanos , Imuno-Histoquímica , Masculino , Prognóstico , Receptor A1 de Adenosina/análise , Valores de Referência , Testes de Função Respiratória , Reação em Cadeia da Polimerase Via Transcriptase Reversa , Medição de Risco , Sensibilidade e Especificidade , Índice de Gravidade de Doença , Regulação para Cima
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA